PVLA Key Statistics, Chart & Performance
The current stock price of PVLA is 92.41 USD. In the past month the price decreased by -5.15%. In the past year, price increased by 561.49%.
PVLA Latest News, Press Relases and Analysis
PVLA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About PVLA
Company Profile
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The company is headquartered in Wayne, Pennsylvania and currently employs 14 full-time employees. The company went IPO on 2014-12-18. The firm is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The firm's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Company Info
PALVELLA THERAPEUTICS INC
353 W. Lancaster Avenue, Suite 200
Wayne PENNSYLVANIA US
Employees: 14
Phone: 14842531461
PALVELLA THERAPEUTICS INC / PVLA FAQ
What does PALVELLA THERAPEUTICS INC do?
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The company is headquartered in Wayne, Pennsylvania and currently employs 14 full-time employees. The company went IPO on 2014-12-18. The firm is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The firm's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
What is the current price of PVLA stock?
The current stock price of PVLA is 92.41 USD. The price decreased by -5.1% in the last trading session.
Does PALVELLA THERAPEUTICS INC pay dividends?
PVLA does not pay a dividend.
What is the ChartMill rating of PALVELLA THERAPEUTICS INC stock?
PVLA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy PVLA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PVLA.
What is the employee count for PVLA stock?
PALVELLA THERAPEUTICS INC (PVLA) currently has 14 employees.
What is the Short Interest ratio of PALVELLA THERAPEUTICS INC (PVLA) stock?
The outstanding short interest for PALVELLA THERAPEUTICS INC (PVLA) is 10.07% of its float.
PVLA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PVLA. When comparing the yearly performance of all stocks, PVLA is one of the better performing stocks in the market, outperforming 99.51% of all stocks.
PVLA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PVLA. The financial health of PVLA is average, but there are quite some concerns on its profitability.
PVLA Financial Highlights
Over the last trailing twelve months PVLA reported a non-GAAP Earnings per Share(EPS) of -5.35. The EPS increased by 73.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.84% | ||
| ROE | -89.05% | ||
| Debt/Equity | 0.41 |
PVLA Forecast & Estimates
21 analysts have analysed PVLA and the average price target is 178.5 USD. This implies a price increase of 93.16% is expected in the next year compared to the current price of 92.41.
For the next year, analysts expect an EPS growth of -16.58% and a revenue growth -100% for PVLA